






This center treats substance use disorders and co-occurring mental health conditions. Your treatment plan addresses each condition at once with personalized, compassionate care for comprehensive healing.
Offering intensive care with 24/7 monitoring, residential treatment is typically 30 days and can cover multiple levels of care. Length can range from 14 to 90 days typically.
This provider hasn't verified their profile's information. Are you the owner of this center? Claim your listing to better manage your presence on Recovery.com.
This center treats substance use disorders and co-occurring mental health conditions. Your treatment plan addresses each condition at once with personalized, compassionate care for comprehensive healing.
Offering intensive care with 24/7 monitoring, residential treatment is typically 30 days and can cover multiple levels of care. Length can range from 14 to 90 days typically.
Chrysalis House only accepts those covered by Medicaid. If you have coverage, your time with us will have no cost for you. If you are uninsured, we can help you apply for Medicaid.
Established in 1986, Chrysalis House is one of the few residential recovery centers in Maryland that allows women to live with their children during treatment, removing a major barrier to care. The program accepts both mothers and women without children, offering services at no cost to clients with Medicaid insurance. Applicants must complete detox and be substance-free for at least 5 days prior to admission.
The residential program is certified at ASAM Level 3.3 and provides 24/7 clinical supervision. Each woman receives an individualized care plan that may include medication-assisted treatment (MAT), substance use disorder education, relapse prevention classes, family counseling, and on-site 12-Step meetings. Additional support includes life skills training, parenting classes, case management, transportation assistance, and on-site infant and child care.
Chrysalis House offers intensive outpatient (ASAM 2.1) and standard outpatient (ASAM 1.0) programs for graduates or as stand-alone care. Individualized plans include counseling, medication-assisted treatment (MAT), relapse prevention, drug testing, and referrals for housing, employment, and community resources. These flexible programs help women maintain recovery, build stability, and stay connected to essential clinical and peer support while transitioning to independent living.

This center treats substance use disorders and co-occurring mental health conditions. Your treatment plan addresses each condition at once with personalized, compassionate care for comprehensive healing.
CARF stands for the Commission on Accreditation of Rehabilitation Facilities. It's an independent, non-profit organization that provides accreditation services for a variety of healthcare services. To be accredited means that the program meets their standards for quality, effectiveness, and person-centered care.

Medication-Assisted Treatment (MAT) is an evidence-based approach that pairs FDA-approved medications with counseling to treat addiction. The medications are used to reduce cravings, ease withdrawal symptoms, or block the effects of substances. More about MAT

Dolophine®, Methadose®
Methadone is a full opioid agonist, meaning it activates opioid receptors in the brain to produce effects like pain relief and euphoria. It is longer acting than many other opioids, making it useful in medication-assisted treatment for opioid use disorder.
It reduces withdrawal symptoms and cravings by occupying opioid receptors without causing intense highs. Because it is a full agonist, it must be used carefully to avoid overdose, but it is highly effective when taken as prescribed within a structured program.

Vivitrol®, Revia®
Naltrexone is an opioid antagonist, meaning it blocks opioid receptors in the brain and prevents opioids from producing effects like euphoria or sedation. It is used to treat both opioid and alcohol use disorders, but does not cause physical dependence or withdrawal.
It helps reduce cravings and the rewarding effects of opioids or alcohol, supporting long-term recovery. Because it blocks opioid effects, it should only be started after a person has fully detoxed from opioids to avoid triggering withdrawal.

Suboxone®, Subutex®, Sublocade®, Zubsolv®
Buprenorphine is a partial opioid agonist used to treat opioid use disorder. It activates opioid receptors to reduce cravings and withdrawal but has a ceiling effect, meaning it produces less euphoria and respiratory depression than full opioids.
Buprenorphine binds tightly to opioid receptors, blocking other opioids from attaching and reducing the risk of misuse. It's often combined with naloxone (as in Suboxone®) to discourage injection misuse and is available in daily or monthly forms.